Please Enter a Search Term

Erin Powell

BA Memorial, BSc. Memorial, MD Memorial FRCPC

Assistant Professor (Medical Oncology) and Residency Program Director (Oncology)

Dr. H. Bliss Murphy Cancer Clinic
300 Prince Phillip Dr.
St. John's, NL  A1B 3V6
t: (709)777-7802 (Clinical)/(709) 777-8751 (Academic)
f: (709) 777-8756

Dr. Erin Powell is a Medical Oncologist at the Dr. H. Bliss Murphy Cancer Center with a focus on Breast Cancer.  She graduated from Memorial University Faculty of Medicine in 2004 and completed her Internal Medicine Residency at Memorial in 2007.  She went on to Medical Oncology training at the University of Ottawa and returned to St. John’s as a Medical Oncologist in 2009.  She is currently the Program Director for the Medical Oncology Training Program which began in 2015.

Dr. Powell is the Chair of the Provincial Breast Disease Site Group and an Assistant Professor, Discipline of Oncology.


Research Interests:

  • Breast
  • GI

Current Research Projects:

  • Supervising Dr. Dawn Armstrong in a chart review regarding rectal cancer

  • Principal Investigator: Cancer Care Program, Eastern Health - A prospective study to evaluate the performance of the 3M Oedema Reduction System (3M-ORS) in patients with lymphedema.

Publications and Poster Presentations:

2010                 M. M. Vickers, E. D. Powell, T. R. Asmis, D. J. Jonker, C. J. O'Callaghan, D. Tu, W. Parulekar, M. J. MooreCo-morbidity and overall survival (OS) in patients with advanced pancreatic cancer (APC): Results from NCIC CTG PA.3 phase III trial of erlotinib plus gemcitabine (E+G) versus gemcitabine (G) alone” J Clin Oncol 28:15s, 2010 (suppl; abstr 4079)


2010                 Asmis TR, Powell E, Karapetis CS, Jonker DJ, Tu D, Jeffery M, Pavlakis N, Gibbs P, Zhu L, Dueck DA, Whittom R, Langer C, O'Callaghan “Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care.” Ann Oncol. 2011 Jan;22(1):118-26. Epub 2010 Jul 5.


2009                 E. D. Powell, D.B. Macdonald, A.M. Elkeilani and T.R. Asmis “A Case of Appendiceal Adenocarcinoma with clinical benefit from FOLFOX and Bevacizumab” Case Rep Oncol 2009;2:111–115


2009                 E. D.Powell, T. Asmis, D. Jonker, D. Tu, C. Karapetis, M. Jeffery, C.O'Callaghan, “Comorbidity and overall survival (OS) in Cetuximab-treated patients with advanced colorectal cancer (ACRC)-results from NCIC CTG CO.17: A phase III trial of cetuximab versus best supportive care (BSC)”, Abstract 4074 ASCO Annual Scientific Meeting 2009


2009                 ED Powell, TR Asmis, D Jonker, D Tu, C Karapetis, M Jeffrey, C O’Callaghan, “Co-morbidity and Overall Survival (OS) in Cetuximab-treated Patients with Advanced Colorectal Cancer (ACRC)-Results form NCIC CTG CO.17: A Phase III Trial of Cetuximab vs. Best Supportive Care (BSC)”, Poster Presentation at the University of Ottawa Resident Research Day


2008                 Powell E and Chow LQM, “BLP-25 liposomal vaccine: a promising potential therapy in non-small cell lung cancer”, Expert Rev. Resp. Med. 2(1), 37-45 (2008)


2007                 Powell  E ., Dwyer P., Greenland J., Laing K., House M. “Evaluation of the Newfoundland and Labrador Teleoncology Program “, Presentation at the Memorial University of Newfoundland Internal Medicine Resident Research Day May 2007

2006                 Powell, E., Dwyer, P., Greenland, J., House, M., Laing, K., Zulfiqar, M. “Development and Application of an Evaluation Framework for a Newfoundland and Labrador Teleoncology Program”, Poster Presentation at the Canadian Association of Medical Oncologists Scientific Meeting, April 2006
Copyright © 2018 Memorial University of Newfoundland.   Newfoundland and Labrador, Canada.